Advances in breast cancer risk modeling: integrating clinics, imaging, pathology and artificial intelligence for personalized risk assessment

Author:

Pesapane Filippo1ORCID,Battaglia Ottavia2,Pellegrino Giuseppe2,Mangione Elisa34,Petitto Salvatore5,Fiol Manna Eliza Del6,Cazzaniga Laura67,Nicosia Luca1,Lazzeroni Matteo6,Corso Giovanni589ORCID,Fusco Nicola38,Cassano Enrico1

Affiliation:

1. Breast Imaging Division, IEO European Institute of Oncology IRCCS, Milan, 20141, Italy

2. Postgraduation School in Radiodiagnostics, Università degli Studi di Milano, Milan, 20141, Italy

3. Division of Pathology, IEO European Institute of Oncology IRCCS, Milan, 20141, Italy

4. School of Pathology, University of Milan, Milan, 20141, Italy

5. Division of Breast Surgery, IEO European Institute of Oncology, IRCCS, Milan, 20141, Italy

6. Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, Milan, 20141, Italy

7. Department of Health Sciences, Medical Genetics, University of Milan, Milan, 20142, Italy

8. Department of Oncology and Hemato-Oncology, University of Milan, Milan, 20141, Italy

9. European Cancer Prevention Organization (ECP), Milan, 20141, Italy

Abstract

Breast cancer risk models represent the likelihood of developing breast cancer based on risk factors. They enable personalized interventions to improve screening programs. Radiologists identify mammographic density as a significant risk factor and test new imaging techniques. Pathologists provide data for risk assessment. Clinicians conduct individual risk assessments and adopt prevention strategies for high-risk subjects. Tumor genetic testing guides personalized screening and treatment decisions. Artificial intelligence in mammography integrates imaging, clinical, genetic and pathological data to develop risk models. Emerging imaging technologies, genetic testing and molecular profiling improve risk model accuracy. The complexity of the disease, limited data availability and model inputs are discussed. A multidisciplinary approach is essential for earlier detection and improved outcomes.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3